Systemic sclerosis, also known as scleroderma, is a rare and complex autoimmune
connective-tissue disease. Once considered an untreatable and unpredictable condition …

Despite the tremendous progress in the clinical management of autoimmune diseases,
many patients do not respond to the currently used treatments. Autoreactive B cells play a …

Rituximab is a human/murine, chimeric anti-CD20 monoclonal antibody with established
efficacy, and a favorable and well-defined safety profile in patients with various CD20 …

Vaccines are among the most impactful public health interventions, preventing millions of
new infections and deaths annually worldwide. However, emerging data suggest that …

Rituximab is a chimeric mouse/human monoclonal antibody (mAb) therapy with binding
specificity to CD20. It was the first therapeutic antibody approved for oncology patients and …

For 20 years, monoclonal antibodies (mAbs) have been a standard component of cancer
therapy, but there is still much room for improvement. Efforts continue to build better cancer …

Successful solid organ transplantation reflects meticulous attention to the details of
immunosuppression, balancing risks for graft rejection against risks for infection. The “net …

Background Rituximab plus chemotherapy, most often CHOP (cyclophosphamide,
doxorubicin, vincristine, and prednisone), is the first-line standard of care for patients with …

The use of monoclonal antibodies (mAbs) for cancer therapy has achieved considerable
success in recent years. Antibody–drug conjugates are powerful new treatment options for …

The idea of synergistic interactions between drugs and chemicals has been an important
issue in the biomedical world for over a century. As complex diseases, especially cancer …